Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
JANX 
Janux Therapeutics Inc (JANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: JANX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $82.46
1 Year Target Price $82.46
| 11 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.19% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.39B USD | Price to earnings Ratio - | 1Y Target Price 82.46 |
Price to earnings Ratio - | 1Y Target Price 82.46 | ||
Volume (30-day avg) 13 | Beta 2.85 | 52 Weeks Range 21.97 - 71.71 | Updated Date 08/29/2025 |
52 Weeks Range 21.97 - 71.71 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.4612 | Actual -0.55 |
Profitability
Profit Margin - | Operating Margin (TTM) -33002.05% |
Management Effectiveness
Return on Assets (TTM) -10.51% | Return on Equity (TTM) -12.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 411344132 | Price to Sales(TTM) 3155.27 |
Enterprise Value 411344132 | Price to Sales(TTM) 3155.27 | ||
Enterprise Value to Revenue 937 | Enterprise Value to EBITDA -33.8 | Shares Outstanding 60093900 | Shares Floating 44967087 |
Shares Outstanding 60093900 | Shares Floating 44967087 | ||
Percent Insiders 6.59 | Percent Institutions 109.9 |
Upturn AI SWOT
Janux Therapeutics Inc
Company Overview
History and Background
Janux Therapeutics, founded in 2017, is a biopharmaceutical company focused on developing novel T-cell engagers that harness the power of the immune system to fight cancer. It went public in 2021 and has been advancing its pipeline since then.
Core Business Areas
- Tumor Activated T-Cell Engager (TATr) Technology: Janux's core technology platform involves developing TATrs, bispecific antibodies designed to selectively activate T cells in the tumor microenvironment while minimizing off-target toxicity.
- Oncology Drug Development: Janux is focused on researching, developing, and commercializing innovative cancer therapies based on its TATr technology.
Leadership and Structure
The leadership team includes David M. Grayzel, M.D. (President and CEO), and the organizational structure is typical for a biotechnology company, with research, development, clinical, and administrative departments.
Top Products and Market Share
Key Offerings
- JANX007: A PSMA-targeting TATr for metastatic castration-resistant prostate cancer (mCRPC). Currently in Phase 1 clinical trials. Market share data is not yet available as it is not yet approved. Competitors include companies developing other PSMA-targeted therapies, such as radioligand therapies and antibody-drug conjugates.
- JANX008: An EGFR-targeting TATr for solid tumors. Currently in preclinical development. Market share data is not yet available as it is not yet approved. Competitors include companies developing other EGFR-targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibodies.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology segment, is experiencing significant growth driven by advancements in immunotherapy and targeted therapies. There is intense competition and high regulatory hurdles.
Positioning
Janux is positioned as an innovator in the T-cell engager space, focusing on tumor-selective activation to improve safety and efficacy. Its TATr technology aims to differentiate it from other T-cell engager approaches.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Janux is positioned to capture a share of this market through its innovative TATr technology, specifically targeting solid tumors and mCRPC.
Upturn SWOT Analysis
Strengths
- Novel TATr technology platform
- Strong intellectual property portfolio
- Experienced management team
- Focus on tumor-selective T-cell activation
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on a single technology platform
- Unproven commercialization capabilities
Opportunities
- Expanding the TATr platform to other cancer targets
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approval of its lead product candidates
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory delays
- Patent challenges
Competitors and Market Share
Key Competitors
- XNCR
- MRTX
- GTHX
Competitive Landscape
Janux is an emerging player in the T-cell engager field. Its TATr technology offers a potential advantage in terms of tumor selectivity, but it faces competition from larger companies with more advanced clinical programs and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by preclinical and initial clinical development activities.
Future Projections: Future growth is dependent on positive clinical trial results and potential partnerships. Analyst estimates will provide more detailed projections.
Recent Initiatives: Recent initiatives include advancing JANX007 and JANX008 through clinical trials and expanding its pipeline with new TATr candidates.
Summary
Janux Therapeutics is a clinical-stage biopharmaceutical company with a novel T-cell engager technology that shows promise. The early stage of development presents risk, but successful clinical trials and potential partnerships could drive significant growth. Its TATr technology, if proven safe and effective, could differentiate it from competitors. Janux needs to manage its cash burn and navigate the regulatory landscape effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share information is estimated and may not be precise. Financial data is based on available public information and may not be up-to-date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Janux Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-06-11 | President, CEO & Director Dr. David Alan Campbell Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | Website https://www.januxrx.com |
Full time employees 103 | Website https://www.januxrx.com | ||
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.